-
What is the difference between PBS and dPBS?(Post)
Lab Buffers · ProtocolsPBS vs DPBS: What’s the Difference?PBS and DPBS are the everyday isotonic, pH-balanced salt solutions used to wash, dilute and transport cells and proteins. This guide bre
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Indusatumab: Advancing Anti-CD47 Cancer Research with Biosimilar Innovations(Post)Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
In Vivo Cell Depletion: Antibody Targets, Fc Mechanisms and Dosing(Post)A depletion experiment is only as good as the depletion you can prove. Injecting a functional-grade antibody and assuming the population is gone is the most common failure mode in in vivo immunology.
Understanding Radial Glial Cells: Insights into Neurodevelopmental Processes(Post)Radial glial cells are essential in shaping the nervous system, serving dual roles in neurogenesis and structural support during the brain's developmental stages. Key Takeaways: Radi
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy(Post)Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors.
Chronic myelogenous leukaemia (CML) – Review(Post)Chronic myelogenous leukaemia (CML) is a myeloproliferative haematopoietic malignancy, characterised by a karyotypic abnormality present in more than 95% of cases known as the Philadelph
Galectin Therapeutics(Post)Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) is a chronic, irreversible and ultimately fatal disease characterized by prog
Your Agonist Antibody Is Not an Agonist(Post)An agonist antibody does not activate its receptor. It gets held still by something else, and the receptors underneath cluster because they are crowded. That sentence sounds like a technicality and i
Myeloid Lineage: Pioneers of Immune Cell Production(Post)Immunology · HaematopoiesisMyeloid Lineage: Pioneers of Immune Cell DevelopmentThe myeloid lineage is one of the two great branches of haematopoiesis, generating the innate immune and blood cells — mo
Assay Genie New Asian Distributor May 2024(Post)Dublin, Ireland — May 20th 2024 — Assay Genie, a leading supplier of ELISA Kits, Antibodies, Cellular Assays, and In Vivo Monoclonal Antibodies, is pleased to announce partnerships with three new
RNA Extraction for COVID-19 Testing(Post)Testing for COVID-19 Since the start of the COVID-19 pandemic, the World Health Organisation have emphasised the crucial importance of
Varlilumab: Unlocking CD27’s Potential in Cancer Research(Post)What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is
Tigatuzumab: Advancing Cancer Research with Targeted Therapies(Post)Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Nadecnemab: Advancing Cancer Research Through Anti-CD47 Targeting(Post)Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu